EUVIMEDEUVIMED entdecken
Open Access

Construction of a versatile fusion protein for targeted therapy and immunotherapy

Xiu-Song Huang, Li-Ting Yang, Ke Yang, Hang Zhou, Tuersunayi Abudureheman, Wei-Wei Zheng, Kai-Ming Chen, Cai-Wen Duan iD

Protein Science · 2024

DOI: 10.1002/pro.4944 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Science, 2024. Verfasst von Xiu-Song Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinicopathological Diagnosis & Research Center, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China. Hauptthemen laut MEDLINE: Neoplasms, Cell-Penetrating Peptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program, Science and Technology Commission of Pudong New Area Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody (Ab)‐based drugs have been widely used in targeted therapies and immunotherapies, leading to significant improvements in tumor therapy. However, the failure of Ab therapy due to the loss of target antigens or Ab modifications that affect its function limits its application. In this study, we expanded the application of antibodies (Abs) by constructing a fusion protein as a versatile tool for Ab‐based target cell detection, delivery, and therapy. We first constructed a SpaC Catcher (SpaCC for short) fusion protein that included the C domains of Staphylococcal protein A (SpaC) and the SpyCatcher. SpaCC conjugated with SpyTag‐X (S‐X) to form the SpaCC‐S‐X complex, which binds non‐covalently to an Ab to form the Ab‐SpaCC‐S‐X protein complex. The “X” can be a variety of small molecules such as fluoresceins, cell‐penetrating peptide TAT, Monomethyl auristatin E (MMAE), and DNA. We found that Ab‐SpaCC‐S‐FITC(−TAT) could be used for target cell detection and delivery. Besides, we synthesized the Ab‐SpaCC‐SN3‐MMAE complex by linking Ab with MMAE by SpaCC, which improved the cytotoxicity of small molecule toxins. Moreover, we constructed an Ab‐DNA complex by conjugating SpaCC with the aptamer (Ap) and found that Ab‐SpaCC‐SN3‐Ap boosted the tumor‐killing function of T‐cells by retargeting tumor cells. Thus, we developed a multifunctional tool that could be used for targeted therapies and immunotherapies, providing a cheap and convenient novel drug development strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCell-Penetrating PeptidesHumansImmunotherapyAntibodiesDNACell Line, Tumor

Stichwörter der Autor:innen

SpaCCSpyCatcher-SpyTag systemcell deliverycell detectionimmunotherapytarget therapy

Substanzen

AntibodiesCell-Penetrating PeptidesDNA

Autor:innen und Institutionen

  • Clinicopathological Diagnosis & Research Center, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
  • Key Laboratory of Tumor Molecular Pathology of Guangxi Higher Education Institutes, Baise, China.
  • Graduate School of Youjiang Medical University for Nationalities, Baise, China.
  • Key Laboratory of Pediatric Hematology and Oncology Ministry of Health and Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shan…
  • Fujian Branch of Shanghai Children's Medical Center Affiliated to SJTU-SM, and Fujian Children's Hospital, Fujian, China.
  • Nanchong Second People's Hospital, Nanchong, China.

ORCID-Profile: Cai-Wen Duan

Förderung

  • National Natural Science Foundation of China
  • Shanghai Sailing Program
  • Science and Technology Commission of Pudong New Area Foundation
  • Guangxi Natural Science Foundation Program
  • Key Laboratory of Tumor Molecular Pathology of Guangxi Higher Education Institutes (Guijiaokeyan [2022]-10)

Zitieren

APA

Huang, X. S., Yang, L. T., Yang, K., Zhou, H., Abudureheman, T., Zheng, W. W., Chen, K. M., & Duan, C. W. (2024). Construction of a versatile fusion protein for targeted therapy and immunotherapy. Protein Science. https://doi.org/10.1002/pro.4944

Vancouver

Huang XS, Yang LT, Yang K, Zhou H, Abudureheman T, Zheng WW, et al. Construction of a versatile fusion protein for targeted therapy and immunotherapy. Protein Science. 2024. doi:10.1002/pro.4944

BibTeX
@article{Huang2024,
  author = {Huang, Xiu-Song and Yang, Li-Ting and Yang, Ke and Zhou, Hang and Abudureheman, Tuersunayi and Zheng, Wei-Wei and Chen, Kai-Ming and Duan, Cai-Wen},
  title = {Construction of a versatile fusion protein for targeted therapy and immunotherapy},
  journal = {Protein Science},
  year = {2024},
  doi = {10.1002/pro.4944}
}
Kostenlos starten →